文献速递淋巴瘤

TLR9依赖性迁移识别BTK抑制下慢性淋巴细胞白血病不同信号状态

TLR9-dependent migration identifies different Chronic Lymphocytic Leukemia signaling states under BTK inhibition.
PubMed 文献 · Blood · 2026-10-05

研究探讨TLR9信号作为BCR阻断的肿瘤应答机制,使用102例TLR9刺激的患者样本发现两种迁移表型:应答者(R)迁移增强,反向应答者(RR)迁移受抑。R样本TLR9信号完整且迁移在BTK抑制下持续,RR样本基础BCR活性高、TLR9信号受抑。BTKi耐药患者TLR9表达更高,复发后BCR信号降低而TLR相关NF-kB信号升高。

要点

  • TLR9刺激可区分CLL患者两种迁移表型:R迁移增强,RR迁移受抑。
  • R样本TLR9信号完整,迁移不依赖BTK,BTK抑制下仍持续。
  • RR样本基础BCR活性高,抑制TLR9应答,TLR9激动不能恢复迁移。

核心结论

  • TLR9依赖性迁移可识别BTK抑制下CLL的不同信号状态,R亚组通过BTK非依赖通路维持迁移。

研究设计与样本

  • 使用102例TLR9刺激的患者样本,结合转录组和蛋白分析、计算机模拟及生化验证。

主要发现

  • TLR9刺激的R样本表达更高IRAK4/IRAK1并诱导NF-kB p100,提示TLR9信号完整。
  • RR样本基础BCR活性升高,IRAK4/IRAK1较低且IRAK1快速降解,提示TLR9信号受抑。
  • 计算机模拟和生化验证显示高基础BCR信号抑制TLR9应答,低基础活性允许TLR9完全激活。
  • R样本TLR9诱导的迁移在BTK抑制下持续,且可被TLR9拮抗消除。
  • BTKi耐药患者CLL细胞TLR9表达更高,复发后BCR信号降低而TLR相关NF-kB信号升高。

局限性

  • 临床部分仅为小型探索性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

B-cell receptor (BCR) inhibitors have transformed chronic lymphocytic leukemia (CLL) therapy, yet many patients show incomplete responses or develop resistance in the absence of Bruton's tyrosine kinase (BTK) mutations. We investigated Toll-like receptor 9 (TLR9) signaling as a tumor-response mechanism to BCR blockade. Using 102 TLR9-stimulated patient samples, we identified two distinct migratory phenotypes: TLR9-induced migratory Responders (R), with enhanced migration, and TLR9-induced migratory Reverse-Responders (RR), with suppression of migration following TLR9 activation. Transcriptomic and protein analyses showed TLR9-stimulated R samples expressed higher IRAK4/IRAK1 and induced NF-kB p100, consistent with intact TLR9 signaling. In contrast, RR samples exhibited elevated basal BCR activity, and lower IRAK4/IRAK1 with rapid IRAK1 degradation, indicating suppressed TLR9 signaling. In-silico modeling and biochemical validation showed high basal BCR signaling suppresses TLR9 responsiveness, whereas low basal activity permits full TLR9 activation. Functionally, TLR9-induced migration persisted despite BTK inhibition (BTKi) in R but not RR samples, and was abrogated by TLR9 antagonism, consistent with signaling through a BTK-independent pathway in the R subgroup. CLL cells from BTKi-resistant patients expressed higher TLR9 and matched pre- and post-relapse samples showed decreased BCR and increased TLR-associated NF-kB signaling post-relapse. Clinically, in small exploratory.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kennedy E, Stott L, Ashworth I, et al. TLR9-dependent migration identifies different Chronic Lymphocytic Leukemia signaling states under BTK inhibition. Blood. 2026. PMID: 42832426. doi:10.1182/blood.2025032914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。